Compare ORN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORN | RIGL |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.4M | 537.6M |
| IPO Year | 2007 | 2000 |
| Metric | ORN | RIGL |
|---|---|---|
| Price | $10.09 | $47.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $11.25 | ★ $43.20 |
| AVG Volume (30 Days) | 239.7K | ★ 567.7K |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | 0.24 | ★ 6.20 |
| Revenue | ★ $835,917,000.00 | $282,076,000.00 |
| Revenue This Year | $6.40 | $65.53 |
| Revenue Next Year | $3.28 | $0.22 |
| P/E Ratio | $42.77 | ★ $6.98 |
| Revenue Growth | 7.02 | ★ 79.13 |
| 52 Week Low | $4.64 | $15.50 |
| 52 Week High | $11.90 | $52.24 |
| Indicator | ORN | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 62.19 |
| Support Level | $9.61 | $40.50 |
| Resistance Level | $10.77 | $43.56 |
| Average True Range (ATR) | 0.36 | 2.04 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 40.26 | 77.33 |
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar and mesh across the light commercial, structural and other associated business areas.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.